Mirikizumab-Mrkz Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 100 mg
Reference Brands: Omvoh (USA)
Category:
Immune Disorder
Mirikizumab-mrkz is available in Injection
and strengths such as 100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Mirikizumab-mrkz is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Mirikizumab-mrkz can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Mirikizumab‑MRKZ, marketed under the brand name Omvoh, is a monoclonal antibody approved for the treatment of moderately to severely active ulcerative colitis in adults. It works by selectively binding to interleukin-23 (IL-23), a cytokine involved in immune-mediated inflammation, and blocking its activity. This targeted mechanism helps reduce inflammation in the gastrointestinal tract and supports mucosal healing, offering a precision-based approach to managing ulcerative colitis.
Administered via subcutaneous injection, Omvoh is designed for patients who have not responded adequately to conventional therapies. The therapy provides a focused immunomodulatory effect while minimizing broader systemic immunosuppression. Patients receiving Omvoh should be monitored for potential adverse events, which most commonly include upper respiratory tract infections, headache, rash, and injection-site reactions. Its development and production are overseen by Eli Lilly and Company in clinical-grade facilities to ensure high-quality manufacturing and safety standards.
Omvoh represents an important therapeutic option in the management of ulcerative colitis, providing targeted disease control and improving patient quality of life through a novel mechanism of action.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing